August 07, 2026

Differing Admission, Testing Patterns Based on Physician Sex

Female physicians ordered more testing and admitted a slightly higher share of patients, without differences in 30-day mortality or short inpatient stays.

MDSpire News

August 05, 2026

AI-Assisted MRI Method May Rival CT in Lung Nodule Detection

A rapid AI‐assisted imaging protocol detected nearly all clinically relevant solid lung nodules while closely matching CT for suspicious screening classifications.

MDSpire News

August 04, 2026

PM2.5 Exposure May Be Linked to Lewy Dementias

Danish registry study found stronger associations for Lewy body dementia than Parkinson's disease–related dementia.

MDSpire News

August 04, 2026

An Overlooked Cause of Pediatric Anaphylaxis

Inhaling cumin during meal preparation triggered the first reported case of pediatric cumin-induced anaphylaxis, raising awareness of spice allergy.

MDSpire News

July 31, 2026

Postsurgical Ensartinib in ALK-Positive NSCLC

Adjuvant ensartinib may represent a new therapeutic strategy in completely resected disease.

MDSpire News

July 30, 2026

Prenatal Alcohol Use May Be on the Rise

National survey data suggest current alcohol use, binge drinking, and heavy drinking became more common during pregnancy from 2011 to 2024, although recent estimates indicated the upward trend may be stabilizing.

MDSpire News

July 30, 2026

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

July 24, 2026

Can Risk Infographic Encourage Smoking Cessation in Patients With COPD?

Physicians delivered smoking cessation counseling more often following implementation, but incomplete intervention delivery highlights the need for randomized evaluation.

MDSpire News

July 23, 2026

FDA Approves Zidesamtinib for ROS1 Lung Cancer

Phase 1/2 ARROS-1 data showed a 44% objective response rate, with most responses ongoing at 6 months.

MDSpire News

July 22, 2026

FDA Expands Pediatric Allergy Nasal Spray Use

A phase 3 randomized, double-blind, placebo-controlled trial in pediatric patients demonstrated improved nasal symptoms compared with placebo.

MDSpire News